Skip to contentG
Guided Therapeutics Inc
G
GTHPGuided Therapeutics Inc Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$60.00K$60.00Kderivedno prior Q4 2020 on file Net Income-$501.00K-$501.00KderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$41,000— Operating Incomederived-$492,000— Operating Cash Flowderived$159,000N/M Free Cash Flowderived$155,000N/M Margins · derivedGross margin68.3%
Operating margin-820.0%
Net margin-835.0%
ended Dec 31, 2021 · filed Mar 30, 2022 · 89 d after period end